Viatris (VTRS) Cash & Equivalents Growth (3y) (2022 - 2026)
Viatris (VTRS) Cash & Equivalents Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | 21.81% |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | 11.05% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | -4.92% |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | 7.80% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 19.10% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 12.11% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 27.55% |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | 13.03% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | 32.82% |
| 10 | Alkermes | 8.17 Bn | 7.51 Bn | 397.90 Mn | -8.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.11% |
| Mar 31, 2026 | 52.71% |
| Dec 31, 2025 | 1.56% |
| Sep 30, 2025 | 14.68% |
| Jun 30, 2025 | -5.19% |
| Mar 31, 2025 | 0.12% |
| Dec 31, 2024 | 1.39% |
| Sep 30, 2024 | 35.41% |
| Jun 30, 2024 | 10.82% |
| Mar 31, 2024 | 7.93% |
| Dec 31, 2023 | 5.28% |
| Mar 31, 2023 | -3.99% |
| Dec 31, 2022 | 36.99% |